Adverum Biotechnologies to Host a Conference Call and Webcast to Present 24-week Data from First Cohort of OPTIC Trial of ADV...
September 04 2019 - 4:01PM
Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene
therapy company targeting unmet medical needs in ocular and rare
diseases, today announced the presentation of interim 24-week data
from the first cohort of patients (n=6) in the OPTIC phase 1
clinical trial of ADVM-022 in wet AMD during a podium presentation
at the Retina Society 2019 Annual Meeting in London on Thursday,
September 12, 2019.
Event: Retina Society 2019 Annual
MeetingPodium Presentation: Interim 24-week Data
from the OPTIC Trial: Phase 1 Study of Intravitreal Gene Therapy
with ADVM-022 (AAV.7m8-aflibercept) for Neovascular (Wet)
Age-related Macular DegenerationDate: September
12, 2019Time: 7:41 – 7:47 am
BSTLocation: The Landmark Hotel, London,
UKSpeaker: Szilard Kiss, M.D., director of
clinical research in the Department of Ophthalmology at Weill
Cornell Medical College
Adverum plans to issue a press release simultaneously with the
presentation of the 24-week data from the first cohort of patients
(n=6) in the OPTIC trial.
Conference Call and WebcastAdverum will host a
conference call and webcast to review the data presented on
September 12, 2019 at 1:30 pm BST (5:30 am PT). Individuals can
participate in the conference call by dialing 1-866-420-8347
(domestic) or 1-409-217-8241 (international), and refer to the
“Adverum Biotechnologies Conference Call.” The webcast will be
accessible under Events and Presentations in the Investors section
of the company’s website. The archived webcast will be available on
the Adverum website following the call, and will be available for
30 days.
About Adverum Biotechnologies, Inc.Adverum is a
clinical-stage gene therapy company targeting unmet medical needs
in ocular and rare diseases. Adverum develops gene therapy product
candidates designed to provide durable efficacy by inducing
sustained expression of a therapeutic protein. Adverum’s core
capabilities include clinical development, novel vector discovery
and in-house manufacturing expertise, specifically in scalable
process development, assay development, and current Good
Manufacturing Practices quality control. For more information,
please visit www.adverum.com.
Investor and Media Inquiries:
Investors:
Myesha Lacy
Vice President, Investor Relations and Corporate Communications
mlacy@adverum.com
650-304-3892
Media:
Joshua R. Mansbach
Solebury Trout
jmansbach@troutgroup.com
646-378-2964
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Aug 2024 to Sep 2024
Adverum Biotechnologies (NASDAQ:ADVM)
Historical Stock Chart
From Sep 2023 to Sep 2024